These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
727 related articles for article (PubMed ID: 24175763)
1. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line. Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763 [TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer]. Tang X; Lu M; Li C; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734 [TBL] [Abstract][Full Text] [Related]
3. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer]. Tang XH; Lu MS; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574 [No Abstract] [Full Text] [Related]
4. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling. Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607 [TBL] [Abstract][Full Text] [Related]
5. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506 [TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line. Wang C; Guo LB; Ma JY; Li YM; Liu HM Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006 [TBL] [Abstract][Full Text] [Related]
8. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells. Lu M; Xiao L; Li Z J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):725-8. PubMed ID: 18231754 [TBL] [Abstract][Full Text] [Related]
9. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol]. Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643 [TBL] [Abstract][Full Text] [Related]
10. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer]. Tang XH; Lu MS; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192 [No Abstract] [Full Text] [Related]
11. Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo. Lu S; Huang Q; Wang Z; Song Y; Wang L J Huazhong Univ Sci Technolog Med Sci; 2009 Oct; 29(5):620-4. PubMed ID: 19821097 [TBL] [Abstract][Full Text] [Related]
12. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells. Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374 [TBL] [Abstract][Full Text] [Related]
13. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605 [TBL] [Abstract][Full Text] [Related]
14. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol]. Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117 [TBL] [Abstract][Full Text] [Related]
15. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179 [TBL] [Abstract][Full Text] [Related]
16. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells. Li Y; Sun J; Gao S; Hu H; Xie P Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518 [TBL] [Abstract][Full Text] [Related]
17. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function. Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Menendez JA; Vellon L; Colomer R; Lupu R Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900 [TBL] [Abstract][Full Text] [Related]
19. Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells. Lu M; Xiao L; Hu J; Deng S; Xu Y J Huazhong Univ Sci Technolog Med Sci; 2008 Aug; 28(4):451-5. PubMed ID: 18704310 [TBL] [Abstract][Full Text] [Related]
20. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]